ESMO Targeted Anticancer Therapies Asia Congress 2026 (ESMO TAT Asia 2026) took place from 12 to 14 June 2026 in Hong Kong SAR, China, bringing together leading researchers, clinicians, industry experts, and innovators dedicated to advancing early-phase cancer drug development and precision oncology across the Asia-Pacific region.
Under the theme “Advancing cancer drug discovery in Asia together ”, the second edition of ESMO TAT Asia continued to build on the momentum of its inaugural congress, serving as a focused platform for discussing the latest progress in targeted anticancer therapies, translational research, biomarker-driven treatment strategies, and novel approaches in clinical trial development.
As oncology moves increasingly toward personalized and molecularly guided care, ESMO TAT Asia 2026 highlighted the growing role of regional and global collaboration in accelerating the journey from scientific discovery to clinical application. The congress offered an important space for experts to exchange knowledge, present emerging data, and shape future directions in targeted cancer treatment.
Scientific Committee Co-Chairs
“Great session on AI driven applications in early drug development on the last day of ESMO TAT Asia 2026 in Hong Kong – chaired by Dr Ho Min Kim (Daejeon, Republic of Korea) and Dr Julien Vibert (Villejuif, France)”
Herbert Loong, MBBS, FRCP, FASCO:
“ESMO TAT Asia 2026 is in full swing in Hong Kong.
Excellent science is being discussed, but even more importantly, wonderful connections are being made.”
“Honoured to have participated in the ESMO Targeted Anticancer Therapies Asia Congress 2026 in Hong Kong, joining colleagues for the session “From Innovation to Implementation in Theranostics and Radioligand Therapy.”
It was a privilege to share the stage with outstanding experts, including Grace Kong, Julie Crouch, Stefan Albrecht, and colleagues from across the region who are driving innovation in precision oncology.
The rapid evolution of theranostics and radioligand therapy is reshaping cancer care, but successful implementation requires much more than scientific breakthroughs. Building sustainable infrastructure, developing multidisciplinary expertise, ensuring equitable access, and generating region-specific evidence will be critical to translating innovation into meaningful patient outcomes across Asia-Pacific.
A special thank you to Professor Brigette B.Y. Ma and the entire organising committee for delivering an exceptional meeting.
With more than 600 attendees, ESMO TAT Asia 2026 highlighted the tremendous momentum and enthusiasm for advancing targeted therapies and fostering collaboration across the region.
The energy, quality of discussions, and commitment to improving patient care were truly inspiring.
Looking forward to continuing these collaborations and accelerating the adoption of innovative therapies for our patients.
Next meeting in Hong Kong: ESMO GU Asia 2027.”
“It was a privilege to present at the ESMO Targeted Anticancer Therapies Meeting in Hong Kong, contributing to the session “From Innovation to Implementation in Theranostics and Radioligand Therapy.”
I was delighted to share this discussion alongside outstanding colleagues, including Grace Kong from Peter MacCallum Cancer Centre, Ravindran Kanesvaran from National Cancer Centre Singapore, and Stefan Albrecht from Novartis.
A sincere thank you to the organisers for delivering an exceptional meeting that brings together global experts and regional leaders to explore cutting-edge science, foster collaboration, and accelerate the translation of novel therapies into clinical practice.”
“Honoured to have been invited to ESMO TAT Asia 2026 in the beautiful city of Hong Kong.
It was an exceptional congress and, above all, a wonderful opportunity for exchanges with our Asian colleagues, planting the seeds for future collaborations and new friendships.
Huge thanks to Janice Tsang and Brigette B.Y. Ma, two outstanding oncologists from Hong Kong, for their warm welcome and friendship.
Excited for what we will build together, beyond borders.”
“Honour to join the second edition of the ESMO Targeted Anticancer Therapies Asia Congress in Hong Kong today and delivered a presentation to highlight latest policies in driving drug market access and clinical trials, as well as government incentives in promoting translational research and drug commercialisation.
The event is highly acclaimed in oncology sector globally and great that Hong Kong has been selected to host this to showcase Hong Kong’s strong commitment to make us an excellence biotech hub in Asia. We shall continue to promote our unique advantages via similar events moving forward.”
“In Hong Kong, discussing research and development in oncology with CSCO.”
“Always a pleasure to meet the amazing ESMO Asia team in Hong Kong.”
“Kicking off ESMO TAT Asia 2026 in Hong Kong.”
“A great final session to end this wonderful conference at ESMO TAT Asia 2026.
The discussion around artificial intelligence balanced excitement with realism.
There are incredible frontiers opening up with the use of AI, but rationality should not be lost in the hype.”
“This week: SuperAI Conference in Singapore, followed by ESMO TAT Asia in Hong Kong — a day’s flight.
Frontier AI and frontier life science are becoming one conversation.
The binding constraint of this synthetic age may not be compute.
It may be trust — and trust is work only humans can do.”
ESMO – European Society for Medical Oncology:
“Congratulations to the ESMO Merit Award recipients at ESMO TAT Asia 2026.
These young researchers were recognised for the scientific merit of their abstracts.
Read more: https://ow.ly/EqCR50Z8EEQ”
“Enjoyed the discussion at ESMO TAT Asia 2026 on bispecific antibodies and STEAP1-targeted T-cell engagers.”
“Excellent sharing by Prof. Xu Ruihua on emerging molecular targets and drugs for cancers prevalent in Asia, with a focus on gastric cancer.
Many new drugs are in the pipeline, especially from China.”
Stay informed with more articles like this on OncoDaily
Written by Nare Hovhannisyan, MD